Key Products

UCB’s medicines are making a real difference to the lives of people all over the world. Some of their products are among the leaders in their field.

Neurology

1. Briviact (brivaracetam) Epilepsy

2. Vimpat (lacosamide) Epilepsy

3. Keppra (levetiracetam) Epilepsy

4. Nayzilam (midazolam) – For US residents only. Epilepsy – Nasal spray

5. Neupro (rotigotine) Parkinson’s disease

6. Neupro (rotigotine) Restless Legs Syndrome

7. Fintepla (fenfluramine) Dravet syndrome / Lennox-Gastaut syndrome

Immunology

1. Cimzia®

2. EVENITY®

3. Bimzelx®

Key Executives

Jean-Christophe Tellier, Chief Executive Officer Chairman of the Executive Committee

Jean-Christophe Tellier joined UCB in 2011. He became UCB’s Chief Executive Officer on January 1, 2015 after having successfully led UCB’s BioBrands and Solutions division as Executive Vice President.

Sandrine Dufour, Executive Vice President Chief Financial Officer Head of Corporate Development

Sandrine Dufour joined UCB as Chief Financial Officer and Head of Corporate Development in July 2020. She is a member of UCB’s Executive Committee. A French national, Sandrine has a proven track record and deep financial expertise that stems from more than 25 years leading successful national and global organizations.

Jean-Luc Fleurial, Executive Vice President Chief Talent Officer

Jean-Luc Fleurial has 20+ years of experience in building and implementing talent strategy across geographies and businesses. He is passionate about people and organization development, building inclusive and innovative culture and is inspired every day by the mission to help patients.

Prof. Dr. Med. Iris Loew-Friedrich, Executive Vice-President Chief Medical Officer

Iris Loew-Friedrich is Chief Medical Officer for UCB, a member of the company’s Executive Committee and Head of the Development Solutions. She provides strategic global leadership for worldwide clinical development, medical affairs, regulatory affairs, quality assurance, statistical innovation, real world evidence and patient safety/pharmacovigilance.

Dhaval Patel, Executive Vice President Chief Scientific Officer

Dhaval Patel leads UCB’s research organization with the main goal of bringing scientific innovation to patients and helping them live the life they choose. Dhaval Patel is a medical doctor and holds a PhD in Microbiology and Immunology. He comes to UCB from Novartis, based in their headquarters in Basel, Switzerland, where for 11 years he led various biomedical research teams in areas of neurology, autoimmunity, transplantation and inflammation. In 2010, he became the Head of Research for the Novartis Institutes for BioMedical Research (NIBR) Europe.

Company Responsibility

UCB knows that the challenges facing the world – from climate change to rising inequalities – are inextricably linked and that every business decision they make has a possible effect on the people they serve, our communities and the planet. UCB sees sustainability as a core requirement that lies at the heart of all they do, driving their ambition to make a positive impact on society and the environment while empowering them to ensure UCB long-term success.

UCB areas of focus are based on a thorough materiality assessment and are at the intersection of their stakeholder expectations and business impact. UCB commitments are not just about minimizing the effect they have on the planet but relate to the ethical approach they take to provide new therapeutic innovations for people living with severe diseases, conduct business and interact with their people, communities and shareholders.

Scientific Innovation

UCB designs, develops and delivers differentiated solutions that help people living with severe diseases live their best possible lives and meet both patient and societal needs. And they do so by ensuring that they are open and transparent, innovating on behalf of patients with the curiosity, empathy and humility needed to truly understand their needs.

Access to Medicines

Every person has a right to healthcare, and UCB does their part to remove barriers to their medicines for those who need them. In the countries where they operate, they are focused on ensuring that all patients who need their medicines have access to them in a way which is viable for patients, society and UCB. In Low- and Medium-Income settings, they develop a social business approach to provide access to quality care and medicines for people with epilepsy.

Employee Health, Safety and Well-being

UCB believes that all people deserve respect and dignity and that the workplace should be a safe, collaborative, respectful, equitable and inclusive environment. UCB cares about the well-being of their people and ensures that all who enter their workplaces are encouraged and supported to grow, learn, and achieve their highest potential.

Diversity, Equity & Inclusion

UCB embraces diversity in all forms. They are strengthened by the diverse perspectives, thoughts, talents, backgrounds and experiences of all their colleagues in their journey to create value for patients, now and into the future. UCB inspires a culture of inclusion by providing to all employees equitable opportunities in recruitment, job assignment, promotion, remuneration, training and benefits.

Ethical Business Practices

UCB creates an environment that promotes and thrives on ethical behaviors. UCB’s vision has always been one of long-term value and sustainable growth, grounded in ethical business practices. When they create value for patients, they grow the value of UCB.

Health of the Planet

UCB’s goal is to develop and deliver medicines for people with severe diseases in the most environmentally sustainable way possible. All their activities have an impact on the environment, and they take their responsibility for the health of the planet very seriously. To live up to their goals, they have set bold targets to minimize our environmental footprint from greenhouse gas emissions, water withdrawal and waste generated through their operations, including those of their business partners.